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Many natural prion diseases of humans and animals are considered to be acquired through
oral consumption of contaminated food or pasture. Determining the route by which prions
establish host infection will identify the important factors that influence oral prion disease
susceptibility and to which intervention strategies can be developed. After exposure, the
early accumulation and replication of prions within small intestinal Peyer’s patches is essen-
tial for the efficient spread of disease to the brain. To replicate within Peyer’s patches, the
prions must first cross the gut epithelium. M cells are specialised epithelial cells within the
epithelia covering Peyer’s patches that transcytose particulate antigens and microorgan-
isms. M cell-development is dependent upon RANKL-RANK-signalling, and mice in which
RANK is deleted only in the gut epithelium completely lack M cells. In the specific absence
of M cells in these mice, the accumulation of prions within Peyer’s patches and the spread of
disease to the brain was blocked, demonstrating a critical role for M cells in the initial transfer
of prions across the gut epithelium in order to establish host infection. Since pathogens,
inflammatory stimuli and aging can modify M cell-density in the gut, these factors may also
influence oral prion disease susceptibility. Mice were therefore treated with RANKL to
enhance M cell density in the gut. We show that prion uptake from the gut lumen was
enhanced in RANKL-treated mice, resulting in shortened survival times and increased dis-
ease susceptibility, equivalent to a 10-fold higher infectious titre of prions. Together these
data demonstrate that M cells are the critical gatekeepers of oral prion infection, whose den-
sity in the gut epithelium directly limits or enhances disease susceptibility. Our data suggest
that factors which alter M cell-density in the gut epithelium may be important risk factors
which influence host susceptibility to orally acquired prion diseases.
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Author Summary
Prion diseases are infectious neurodegenerative disorders that affect humans and animals.
Many natural prion diseases are orally acquired through consumption of contaminated
food or pasture. An understanding of how prions infect the intestine will help identify fac-
tors that influence disease susceptibility and allow the development of new treatments.
After oral infection prions first accumulate within the lymphoid tissues that line the intes-
tine (known as Peyer’s patches) before they spread to the brain where they cause neurode-
generation. To do this, the prions must first cross the intestinal epithelium, a single layer
of cells that separates the body from the gut contents. M cells are found within the epithe-
lium that covers the Peyer’s patches and are specialised to transport large particles and
whole bacteria across the gut epithelium. We show that M cells act as the gatekeepers of
oral prion infection. In the absence of M cells, oral prion infection is blocked, whereas an
increase in M cells increases the risk of prion infection and shortens the disease duration.
Therefore, our data demonstrate that factors such as pathogen infection, inflammation
and aging, which alter the abundance of M cells in the intestine, may be important risk
factors which influence susceptibility to orally-acquired prion infections.
Introduction
Prion diseases (transmissible spongiform encephalopathies) are a unique group of subacute
neurodegenerative diseases that affect humans and animals. During prion disease, aggrega-
tions of PrPSc, an abnormally folded isoform of cellular PrP (PrPC), accumulate in affected tis-
sues. Prion infectivity co-purifies with PrPSc and constitutes the major, if not sole, component
of the infectious agent [1–3]. Many natural prion diseases, including natural sheep scrapie,
bovine spongiform encephalopathy (BSE), chronic wasting disease in cervids, and variant
Creutzfeldt-Jakob disease in humans (vCJD), are acquired peripherally, such as by oral con-
sumption of prion-contaminated food or pasture. The precise mechanism by which orally-
acquired prions are propagated from the gut lumen across the epithelium to establish host
infection is uncertain. In the U.K. relatively few vCJD cases have fortunately occurred despite
widespread dietary exposure to BSE [4], suggesting that the acquisition of prions from the gut
lumen may differ between individuals. Further studies are clearly necessary to precisely char-
acterise the cellular route that prions exploit to establish infection after oral exposure, and how
alterations to this cellular route, both intrinsic and extrinsic, can affect disease susceptibility.
Treatments which prevent the accumulation and replication of prions in host lymphoid tissues
can significantly reduce disease susceptibility [5–9]. Therefore, identification of the cellular
route by which prions are first transported across the gut epithelium to achieve host infection
will identify an important factor which influences oral prion disease susceptibility and to
which intervention strategies can be developed.
Following oral exposure the early accumulation and replication of prions upon follicular
dendritic cells (FDC) within the gut associated lymphoid tissues (GALT), such as Peyer’s
patches of the small intestine, is essential for efficient neuroinvasion [7, 10–13]. FDC are a
unique subset of stromal cells resident within the primary B cell follicles and germinal cen-
tres of lymphoid tissues [14]. After amplification upon the surface of FDC [15], the prions
then infect neighbouring enteric nerves and spread along these to the CNS (a process
termed neuroinvasion) where they ultimately cause neurodegeneration and death of the
host [16–19].
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The follicle-associated epithelia (FAE) which covers the lumenal surfaces of the Peyer’s
patches contains a unique population of epithelial cells, termed M cells. These highly phago-
cytic epithelial cells are specialized for the trans-epithelial transfer of particulate antigens and
microorganisms from the gut lumen (termed transcytosis) [20], an important initial step in the
induction of efficient mucosal immune responses against certain pathogenic bacteria [21, 22]
and the commensal bacterial flora [23]. A variety of bacterial and viral pathogens including
Brucella abortus [24], Salmonella Typhimurium [25], Yersinia enterocolitica [26], norovirus
[27, 28] and reovirus [28] appear to exploit the transcytotic activity of M cells to cross the gut
epithelium and infect the host. The food-borne botulinum neurotoxin [29] has also been sug-
gested to exert its toxicity after transcytosis by M cells [29]. Independent studies suggest orally
administered prions may similarly be transported by M cells into host tissues [9, 30–32] and
that this transport may be important to establish host infection [9]. Other studies have also
suggested that prions can be transported across the gut epithelium via enterocytes, indepen-
dently of M cells [16, 33, 34], however to what extent enterocyte-transported prions contribute
to the establishment of host infection has not been assessed.
The differentiation of M cells from uncommitted precursors in the intestinal crypts is crit-
ically dependent on stimulation from the cytokine known as RANKL (receptor activator of
nuclear factor-κB ligand). This cytokine is expressed by subepithelial stromal cells beneath
the FAE in Peyer’s patches, and signals via its receptor RANK (receptor activator of nuclear
factor-κB) which is expressed by epithelial cells throughout the intestine [35]. Accordingly,
M cell-differentiation is blocked in RANKL-deficient mice or following in vivo RANKL-neu-
tralization with anti-RANKL antibody [35]. RANKL stimulation induces a program of gene
expression in intestinal epithelial cells which includes the transcription factor SPIB. Expres-
sion of SPIB by intestinal epithelial cells is essential for their differentiation and functional
maturation into M cells [22, 36, 37]. We have previously reported that the early accumulation
of prions upon FDC in Peyer’s patches and subsequent neuroinvasion were blocked in mice
in which M cells were transiently depleted by RANKL-neutralization using anti-RANKL
antibody [9]. However, since RANKL-RANK signalling has multiple roles in the immune
system, a more refined model is required to specifically determine the role of M cells in oral
prion disease pathogenesis. In the current study a unique conditional knockout mouse
model was used in which RANK expression was specifically deleted only in the intestinal epi-
thelium (RANKΔIEC mice) [23, 38]. In these mice the complete loss of M cells prevents M
cell-mediated antigen uptake from the gut lumen, without altering other RANKL-RANK sig-
nalling events required for normal immune development and function [23, 38]. Using these
mice our data clearly show that M cells are critically required for the initial trans-epithelial
transfer of prions across the gut epithelium into Peyer’s patches in order to establish host
infection.
Certain pathogenic bacteria [25, 39] or exposure to inflammatory stimuli such as cholera
toxin [40] can significantly increase the density of M cells in the intestine. Inflammation or
pathogen infection can also influence prion disease pathogenesis by enhancing the uptake, or
expanding the distribution, of prions within the host [11, 41–43]. This raised the hypothesis
that exposure to inflammatory stimuli that enhance M cell-density might increase oral prion
disease susceptibility by enhancing the uptake of prions from the gut lumen. We show that
increased M cell-density at the time of oral exposure dramatically enhanced the uptake of pri-
ons from the gut lumen, decreased survival times and increased disease susceptibility by
approximately 10-fold. Our data provide a significant advance in our understanding of how
prions exploit M cells to initially infect Peyer’s patches and how factors that increase the den-
sity of M cells in the gut epithelium, such as concurrent pathogen infection, may have the
potential to increase susceptibility to orally-acquired prion infection.
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Results
RANK-deficiency only in the intestinal epithelium specifically blocks M
cell-development
Our previous study showed that oral prion infection was blocked after transient M cell-deple-
tion by treatment with anti-RANKL antibody, implying a functional role for M cells in the traf-
ficking of prions from the lumen into GALT in vivo [9]. Although the major phenotype
observed in the intestine was a transient loss of mature M cells, RANKL-RANK signalling is
also important in immune system and lymphoid tissue development. Therefore, systemic
RANKL neutralization by treatment with anti-RANKL antibody could have affected other
important cellular processes involved in prion pathogenesis. To exclude these, we used a more
refined model of M cell-deficiency, RANKΔIEC mice [23, 38], to further elucidate the role of M
cells in the transport of prions from the intestinal lumen into GALT. These mice are specifi-
cally deficient in Tnfrsf11a (which encodes RANK) only in Vil1-expressing intestinal epithelial
cells. As previously published [23], whole-mount immunostaining for the mature M cell
marker glycoprotein 2 (GP2; [21, 22]) revealed an absence of GP2+ M cells in the FAE of the
Peyer’s patches of RANKΔIEC mice compared to control (RANKF/F) mice (Fig 1A & 1B). Coin-
cident with the loss of RANK expression in the gut epithelium was a significant reduction in
area of the FAE (Fig 1C).
Assessment of the uptake of fluorescent latex microbeads from the gut lumen into Peyer’s
patches is a reliable in vivo method to compare the functional ability of M cells to acquire and
transcytose particulate antigens. Here, RANKΔIEC mice and RANKF/F control mice (n = 3/
group) were orally gavaged with 2x1011 200 nm fluorescent microbeads, and 24 h later the
number of microbeads in their Peyer’s patches quantified by fluorescence microscopy. This
duration was selected to ensure sufficient time for the beads to transit through the intestine
and be transcytosed by M cells in the FAE overlying the Peyer’s patches [13]. Coincident with
the absence of mature GP2+ M cells, RANKΔIEC mice had substantially less fluorescent
microbeads within the subepithelial dome (SED) regions of their Peyer’s patches when com-
pared to controls (Fig 1D), indicating a dramatic reduction in the ability to sample particulate
antigen from the gut lumen.
RANK-dependent GP2+ M cells have been described in the epithelium of the nasal associ-
ated lymphoid tissue (NALT) [44, 45]. The abundance of GP2+ M cells in the NALT was unaf-
fected in RANKΔIEC mice (Fig 1E), highlighting the intestinal specificity of the model.
In addition to being transported through M cells, prions have also been observed trafficking
into Peyer’s patches through the large LAMP1+ endosomes of FAE enterocytes [16]. Immuno-
histochemical (IHC) analysis of LAMP1 expression showed that these endosomes were still
present in the FAE of RANKΔIEC mice (Fig 1F). If the presence of these endosomes in the FAE
was dependent on RANKL-RANK signalling, we reasoned that the abundance of LAMP1+
immunostaining would be decreased in the FAE of RANKΔIEC mice. However, morphometric
analysis indicated equivalent areas of LAMP1+ immunostaining in the FAE of RANKΔIEC and
RANKF/F mice (Fig 1G). These data suggest that the presence of LAMP1+ endosomes in the
FAE was not RANKL-RANK signalling dependent.
Antigens that are transcytosed by M cells are released into their basolateral pockets where
they are sampled by lymphocytes and mononuclear phagocytes (MNP; a heterogeneous popu-
lation of macrophages and classical dendritic cells; DC) [46–48]. The acquisition of prions by
MNP such as CD11c+ classical DC may mediate their initial transport to FDC [8, 16, 49], and
the subsequent transfer of prions from FDC to the peripheral nervous system [50–52]. IHC
and morphometric analysis revealed a significant reduction in the % area of CD11c-specific
immunostaining in the SED of the Peyer’s patches from RANKΔIEC mice (Fig 2A & 2B),
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Fig 1. RANKΔIEC mice specifically lack intestinal M cells. A) Peyer’s patches from RANKF/F and RANKΔIEC mice were whole-mount
immunostained to detect M cells (GP2+ cells, green) and F-actin (blue) as a counterstain. The broken line indicates the boundary of the follicle
associated epithelium (FAE) overlying the Peyer’s patches. V, villi. This immunohistochemical (IHC) analysis indicated an absence of GP2+ M cells in
the FAE of RANKΔIEC mice. B) Morphometric analysis confirmed that the number of GP2+ cells/FAE was significantly reduced in RANKΔIEC mice
(P<0.0001, Mann-Whitney U test). C) The size of the FAE area was also significantly reduced in RANKΔIEC mice (P<0.0001, Student’s t-test; data
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whereas the % area of CD68-specific immunostaining (indicative of tissue macrophages) was
equivalent in RANKΔIEC and RANKF/F mice (Fig 2A & 2C). Analysis of the intestinal lamina
propria (LP) showed a similar trend (Fig 2D–2F).
Following replication upon FDC, the prions subsequently infect enteric nerves (both sym-
pathetic and parasympathetic) to reach the CNS where they ultimately cause neurodegenera-
tive disease [16, 18]. Our IHC analysis of the expression of the neuronal synaptic vesicle
marker synaptophysin 1 suggested that the magnitude of the enteric innervation in the LP was
similar in the intestines of RANKΔIEC and RANKF/F mice (Fig 2G & 2H).
Together these data demonstrate that RANKΔIEC mice represent a refined model in which
to study the specific role of M cells in oral prion disease pathogenesis.
Prion accumulation and dissemination after intra-peritoneal injection is
preserved in RANKΔIEC mice
The early replication of many prion strains upon FDC within the B cell-follicles of the draining
lymphoid tissues is essential for their efficient transmission to the CNS after peripheral expo-
sure [5–7, 15]. FDC in mice characteristically express high levels of CD21/35 (complement
receptors 2 & 1, respectively). Our IHC analysis showed that the area of CD21/35-specific
immunostaining in Peyer’s patches of 10 wk old RANKΔIEC and RANKF/F mice was similar
(Fig 3A & 3B), suggesting that the size of the FDC networks (CD21/35+ cells) in the Peyer’s
patches of each mouse strain was equivalent. The replication of prions upon FDC is critically
dependent on their expression of PrPC [15, 53, 54]. Morphometric analysis also indicated that
the magnitude of the PrPC-expression co-localized upon CD21/35+ FDC in the Peyer’s patches
(Fig 3A & 3C) and mesenteric lymph nodes (MLN) (Fig 3D & 3E) of RANKΔIEC mice and
RANKF/F mice was similar.
We next determined whether the FDC in the lymphoid tissues of RANKΔIEC mice were
capable of accumulating prions to a similar extent as those of control mice. After injection by
the intra-peritoneal (i.p.) route high levels of prion accumulation and replication are first
detected in the spleen within 35 d post infection (dpi) [53]. The prions are then subsequently
disseminated around the host via the blood and lymph to most other secondary lymphoid tis-
sues [55]. Furthermore, by 140 dpi the prions are also detectable within Peyer’s patches. Since
the prions do not need to cross the gut epithelium to eventually infect the Peyer’s patches after
injection by the i.p. route, RANKΔIEC and RANKF/F were injected with a 1% dose of ME7 scra-
pie prions via this route and tissues collected at 140 dpi, to determine whether the FDC in the
lymphoid tissues of RANKΔIEC mice were capable of accumulating prions. Prion disease-spe-
cific accumulations of PrP (referred to as PrPd) were detected by immunostaining for the
abnormal aggregates of PrP characteristically present only in affected tissues [6, 9, 11, 13, 53,
56], complimented with paraffin-embedded tissue (PET) blot analysis of adjacent membrane-
bound sections to confirm that these aggregates contained relatively proteinase-K (PK)-
derived from 4 FAE/mouse, n = 3–5 mice/group). D) To compare the functional ability of M cells in the FAE of RANKΔIEC and RANKF/F control mice to
transcytose particulate antigens, mice were orally gavaged with 200 nm fluorescent microbeads and 24 h later, the presence of the microbeads in their
Peyer’s patches was determined by fluorescence microscopy. The uptake of microbeads into the Peyer’s patches of RANKΔIEC mice was significantly
impaired when compared to RANKF/F mice (P<0.0001, Mann-Whitney U test; data derived from 21–31 sections of Peyer’s patches/mouse, n = 3 mice/
group). E) Whole-mount IHC analysis revealed that GP2+ M cells (green) were abundant in the nasal associated lymphoid tissues of RANKF/F and
RANKΔIEC mice. F-actin (blue) was used as a counterstain. The boxed area in the left-hand images is shown at higher magnification in the right-hand
images. F) IHC analysis was used to compare the presence of large LAMP1+ endosomes (red) within enterocytes in FAE of Peyer’s patches from
RANKF/F and RANKΔIEC mice. Sections were counterstained with DAPI (blue) to detect cell nuclei. The broken lines indicate the boundary of the FAE.
SED, subepithelial dome. G) Morphometric analysis revealed that the area of the LAMP1+ immunostaining in the FAE of RANKF/F and RANKΔIEC mice
was similar (P = 0.258, Student’s t-test; data derived from 2–8 FAE/mouse, n = 3 mice/group), suggesting that the formation of the large LAMP1+
endosomes in FAE enterocytes was not influenced by RANK-deficiency in the gut epithelium.
doi:10.1371/journal.ppat.1006075.g001
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Fig 2. Effect of intestinal epithelial cell-specific RANK-deficiency on mononuclear phagocytes and innervation in the
lamina propria. A) Immunohistochemical (IHC) comparison of the distribution of CD11c+ (green) and CD68+ (red) mononuclear
phagocytes (indicative of classical DC and tissue macrophages, respectively) in Peyer’s patches from RANKF/F and RANKΔIEC
mice. Sections were counterstained with DAPI (blue) to detect cell nuclei. Broken line shows the lumenal boundary of the follicle
associated epithelium. SED, subepithelial dome. Morphometric analysis revealed that (B) the % area of the SED occupied by
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resistant prion disease-specific PrPSc [57]. Abundant accumulations of PrPSc were evident in
association with FDC (CD21/35+ cells) in the Peyer’s patches, MLN and spleens of RANKΔIEC
and RANKF/F mice (Fig 4A–4C). These data clearly show that the FDC in the Peyer’s patches,
MLN and spleen of RANKΔIEC mice were functionally capable of acquiring and accumulating
prions, and that the dissemination of prions between lymphoid tissues was not impaired.
Importantly, these data also suggest that the cause of any difference in prion pathogenesis
between RANKΔIEC and RANKF/F mice observed after oral exposure would be restricted to
effects on M cells in the gut epithelium.
RANKΔIEC mice are resistant to oral prion infection
Within weeks after oral exposure, high levels of ME7 scrapie prions first accumulate upon
FDC in the Peyer’s patches and subsequently spread to the MLN and spleen [7–9, 11, 13]. The
initial replication of prions upon FDC in the Peyer’s patches is essential for the efficient trans-
mission of disease to the CNS [7, 11, 13]. In order to determine the effect of specific M cell-
deficiency on oral prion disease pathogenesis, RANKΔIEC mice and RANKF/F (control) mice
were orally exposed to a moderate dose of ME7 scrapie prions (50 μl of a 1% brain homogenate
from a mouse clinically-affected with ME7 scrapie prions; [7, 9, 11, 13, 58]). At intervals after
exposure the accumulation of PrPd and PrPSc in tissues from 4 mice/group were compared by
IHC and PET blot analysis, respectively, as above. As anticipated, at 105 dpi, abundant accu-
mulations of PrPd (middle row, brown) and PrPSc (lower row, black) were detected in associa-
tion with FDC (CD21/35+ cells, upper row, brown) in the Peyer’s patches, MLN and spleen of
RANKF/F control mice (Fig 5A). However, no PrPSc accumulations were detected in the same
tissues from RANKΔIEC mice (Fig 5A). Mice on a C57BL/6 background typically succumb to a
moderate dose of ME7 scrapie prions by ~340 d after oral exposure [9, 13]. However, RAN-
KΔIEC mice (n = 8) remained free of the clinical signs of prion disease up to at least 440 dpi, at
which point no PrPd or PrPSc was detected in their Peyer’s patches, MLN, spleen (Fig 5B), spi-
nal cords or brains (Fig 5C) by IHC and PET blot analysis. Together these data clearly show
that M cells are essential for the initial uptake of prions from the gut lumen into Peyer’s
patches in order to establish host infection, since oral prion disease pathogenesis was blocked
in the specific absence of M cells in RANKΔIEC mice.
RANKL-treatment promotes M cell development in the FAE and villous
epithelium
Certain pathogen infections or inflammatory conditions can enhance M cell-differentiation
within the intestine [25, 39, 40]. We therefore reasoned that alterations to M cell-density in the
gut epithelium may significantly alter oral prion disease pathogenesis and susceptibility. The
density of functionally mature M cells in the intestine can be promoted in mice through
CD11c+ immunostaining was significantly reduced in RANKΔIEC mice (P < 0.001, Mann-Whitney U test), whereas (C) the % area
occupied by CD68+ immunostaining was similar between each mouse group (P = 0.201, Student’s t-test; data derived from 1–10
SED/mouse, n = 6–7 mice/group). D) IHC comparison of the distribution of CD11c+ (green) and CD68+ (red) mononuclear
phagocytes in the lamina propria (LP) of RANKF/F and RANKΔIEC mice. Sections were counterstained with DAPI (blue).
Morphometric analysis revealed that (E) the % area of the CD11c+ immunostaining was also significantly reduced in the LP of
RANKΔIEC mice (P < 0.025, Mann-Whitney U test), whereas (F) the % area of CD68+ immunostaining was similar (P = 0.718,
Student’s t-test; data derived from 1–6 LP areas/mouse, n = 7 mice/group). G) Sections of intestine from RANKF/F and RANKΔIEC
mice were immunostained to identify synaptophysin 1 (red) within synaptic vesicles, enabling the enteric innervation in the gut wall
to be compared. Sections were counterstained with DAPI (blue). H) Morphometric analysis revealed that the % area of
synaptophysin 1+ immunostaining within the LP of RANKF/F and RANKΔIEC mice was similar (P = 0.433, Mann-Whitney U test; data
derived from 2 LP areas/mouse, n = 4 mice/group). These data implied that RANK-deficiency in the gut epithelium did not influence
the enteric innervation in the gut wall.
doi:10.1371/journal.ppat.1006075.g002
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exogenous administration of RANKL [22, 35]. Recombinant RANKL was prepared and its
ability to stimulate M cell-differentiation was confirmed in in vitro intestinal enteroids derived
from RANKΔIEC and RANKF/F mice [23, 36]. As anticipated, RANKL-treatment of enteroids
from RANKF/F (control) mice induced robust expression of several M cell-associated genes
Fig 3. Follicular dendritic cells status in RANKΔIEC mice. Immunohistochemical (IHC) and morphometric analyses were used to
compare follicular dendritic cell (FDC) status in the Peyer’s patches and mesenteric lymph nodes (MLN) of RANKΔIEC and RANKF/F control
mice. A) IHC comparison of CD21/35 (red) and PrPC (blue, lower panels) expression by FDC in the B cell-follicles (B220+ cells, green) of
Peyer’s patches from RANKF/F and RANKΔIEC mice. Broken lines show the lumenal surface of the follicle-associated epithelium. V, villi (V).
Cell nuclei in the upper panels were counterstained with DAPI (blue). B) Morphometric analysis revealed that the area of the CD21/35+
immunostaining in Peyer’s patches from RANKF/F and RANKΔIEC mice was similar, implying that the FDC networks (CD21/35+ cells) in
these tissues were of equivalent size (P = 0.591, Student’s t-test; data derived from 2–9 B cell-follicles/mouse, n = 7 mice/group). C)
Morphometric analysis suggested that the % area of PrPC immunostaining within the FDC networks was similar in Peyer’s patches from
RANKF/F and RANKΔIEC mice (P = 0.573, Mann-Whitney U test; data derived from 2–9 B cell-follicles/mouse, n = 7 mice/group). D)
Sections of MLN from RANKF/F and RANKΔIEC mice were immunostained to detect B cells (B220, green), FDC (CD21/35+ cells, red) and
PrPC (blue). E) Morphometric analysis also revealed that the % area of PrPC immunostaining within the FDC networks was similar in the
MLN from RANKF/F and RANKΔIEC mice (P = 0.689, Student’s t-test; data derived from 3 B cell-follicles/mouse, n = 4 mice/group).
doi:10.1371/journal.ppat.1006075.g003
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Fig 4. Prion accumulation upon follicular dendritic cells (FDC) after intra-peritoneal injection is preserved in RANKΔIEC mice.
Since prions do not need to cross the gut epithelium to eventually infect Peyer’s patches after injection by the intra-peritoneal route,
RANKΔIEC and RANKF/F (control) were injected with a 1% dose of ME7 scrapie prions via this route and tissues collected at 140 d post-
infection, to determine whether the FDC in the lymphoid tissues of RANKΔIEC mice were capable of accumulating prions. High levels of
disease-specific PrP (PrPd, brown, middle rows) were detected in association with FDC (CD21/35+ cells, brown, upper panels) in the
Increased M Cell-Density Exacerbates Oral Prion Disease Susceptibility
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(Marcksl1, Anxa5, Spib, Ccl9, and Gp2; [22]) without significantly altering expression of genes
associated with other intestinal lineages, including Paneth cells (Lyz1, Lyz2) and intestinal
stem cells (Lgr5) (S1 Fig). No induction of expression of M cell-specific genes was observed in
RANKL-treated enteroids derived from RANKΔIEC mice.
Next, C57BL/6 mice (n = 4/group) were treated daily with RANKL to induce M cell-differ-
entiation and tissues harvested on d 3, coincident with the peak period of induction of M cell
gene expression in the gut epithelium [22, 35]. A parallel group of mice were treated with PBS
as a control. IHC and morphometric analysis revealed that RANKL-treatment induced a sig-
nificant increase in the number of GP2-expressing (mature) and SPIB-expressing (differentiat-
ing and mature) M cells within the FAE of Peyer’s patches (Fig 6A–6C) and also in the villous
epithelium (Fig 6D–6F). This increase in M cells was associated with increased functional abil-
ity to acquire particulate antigen from the gut lumen, demonstrated by a significant increase in
the number of 200 nm microbeads transcytosed into the SED of Peyer’s patches and villous
cores 24 h after their administration by oral gavage (Fig 6G–6I). Although a small increase in
the area of LAMP1+ immunostaining was observed in the FAE after RANKL treatment, the
abundance of LAMP1+ immunostaining was unchanged in the villous epithelium (Fig 6J–6L).
We also determined whether RANKL-treatment affected other important parameters con-
sidered to be required for prion infection. IHC and morphometric analysis suggested there
was no significant difference in the area of CD21/35+ (indicative of FDC size) or PrPC+ immu-
nostaining in the Peyer’s patches (S2A–S2C Fig) or MLN (S2D & S2E Fig) of RANKL-treated
mice when compared to PBS-treated controls. This implied that RANKL-treatment had no sig-
nificant effect on FDC status in the Peyer’s patches or MLN.
IHC and morphometric analysis also indicated that the % area of CD11c+ immunostaining
in the SED of the Peyer’s patches (Fig 7A & 7B) and the LP (Fig 7D & 7E) did not differ
between tissues from PBS- and RANKL-treated mice. Although the % area of CD68+ immu-
nostaining was equivalent in the SED of the Peyer’s patches (Fig 7A & 7C), a significant
increase was observed in the LP of RANKL-treated mice (Fig 7D & 7F). No difference in the %
area of synaptophsyin 1+ immunostaining was observed in the LP (Fig 7G & 7H), suggesting
that RANKL-treatment did not significantly affect the magnitude of the enteric innervation in
the intestine.
Together, these data demonstrate that RANKL-treatment promotes M cell-differentiation
in the FAE of Peyer’s patches and villous epithelium without significant effects on other key
cells (FDC, CD11c+ cells and enteric nerves) considered to play an important role in oral
prion disease pathogenesis.
Increased M cell-density enhances susceptibility to oral prion disease
To determine whether increased M cell-density in the intestine altered oral prion disease sus-
ceptibility, groups of C57BL/6 mice were treated daily with RANKL (or PBS as a control) for 4
d as above, and between the 3rd and 4th treatments (coincident with the peak period of induc-
tion of M-cell gene expression in the gut epithelium [22, 35]) the mice were orally exposed to
either a moderate (1%) or limiting (0.1%) dose of ME7 scrapie prions. Exposure of C57BL/6
mice to a 1% dose of prions typically yields a clinical disease incidence of 100% in the recipi-
ents, whereas a 0.1% dose has a much lower incidence allowing the effects of RANKL-treat-
ment on both survival time and prion disease susceptibility to be assessed. As anticipated,
Peyer’s patches (A), mesenteric lymph nodes (MLN, B), and spleens (C) of mice from each group. Sections were counterstained with
haematoxylin to detect cell nuclei (blue). Analysis of adjacent sections by PET immunoblot analysis confirmed the presence of prion-
specific PK-resistant PrPSc (blue/black). Images are representative of 4 mice/group.
doi:10.1371/journal.ppat.1006075.g004
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Fig 5. PrPSc accumulation upon follicular dendritic cells (FDC) after oral prion exposure is blocked in RANKΔIEC mice. In order to determine the
effect of specific M cell-deficiency on oral prion pathogenesis, RANKΔIEC mice and RANKF/F (control) mice were orally-exposed to a 1% dose of ME7
scrapie prions and tissues collected at intervals afterwards. At 105 d post infection (dpi) high levels of disease-specific PrP (PrPd, brown, middle rows)
were detected in association with FDC (CD21/35+ cells, brown, upper panels) in (A) the Peyer’s patches, (B) mesenteric lymph nodes (MLN), and (C)
spleens of RANKF/F control mice. Analysis of adjacent sections by PET immunoblot analysis confirmed the presence of prion-specific PK-resistant PrPSc
(blue/black). Arrows show PrPd/PrPSc accumulation upon FDC networks. In contrast, no PrPSc was detected in any of the Peyer’s patches, MLN and
spleens from orally-exposed RANKΔIEC mice at (A) 105 dpi or (B) 440 dpi. C) Similarly, no PrPSc was detected in any of the spinal cords or brains of orally-
exposed RANKΔIEC mice at 440 dpi. Sections were counterstained with haematoxylin to detect cell nuclei (blue). Images are representative of 8 orally-
exposed RANKΔIEC mice.
doi:10.1371/journal.ppat.1006075.g005
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Fig 6. RANKL treatment enhances the density of M cells in the follicle associated epithelium (FAE) of the
Peyer’s patches and the villous epithelium of the intestine. The density of functionally mature M cells in the
intestine can be promoted in mice through exogenous administration of RANKL. Here, C57BL/6 mice were treated
daily with RANKL (or PBS as a control) to induce M cell-differentiation. Peyer’s patches and intestines were
collected on d 3 of treatment, coincident with the peak period of induction of M-cell gene expression in the gut
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following oral exposure to a moderate (1%) dose of ME7 scrapie prions, all PBS and RANKL-
treated mice developed clinical disease. However, the RANKL-treated mice succumbed to clin-
ical disease approximately 17 d earlier with a shorter mean survival time when compared to
PBS-treated control mice (PBS-treated mice, mean 346±25 d, median 343 d, n = 7/7; RANKL-
treated mice, mean 329±18 d, median 322 d, n = 8/8; Fig 8A). When mice were orally exposed
to a limiting (0.1%) dose of prions only three of eight PBS-treated mice succumbed to clinical
disease with individual survival times of 371, 378 and 420 d (Fig 8A). The five remaining PBS-
treated mice did not develop clinical prion disease up to 525 dpi. In contrast, RANKL-treat-
ment significantly enhanced prion disease pathogenesis as seven of eight RANKL-treated mice
exposed to a limiting dose of prions succumbed to clinical disease with significantly shorter
survival times (Fig 8A; RANKL-treated mice, mean 352±22 d, median 350 d, n = 7/8;
P<0.0078, Log-rank [Mantel-Cox] test). Only one of the eight RANKL-treated mice exposed
to a limiting dose of prions was free of the clinical signs of prion disease up to at least 525 dpi.
The brains of all mice that developed clinical signs of prion disease in each treatment
group had the characteristic spongiform pathology (vacuolation), astrogliosis, microgliosis
and PrPSc accumulation typically associated with terminal infection with ME7 scrapie prions
(Fig 8B). The distribution and severity of the spongiform pathology was also similar in the
brains of all the clinically-affected mice (Fig 8C & 8D), indicating that RANKL treatment did
not alter the course of CNS prions disease after neuroinvasion had occurred. In contrast, no
histopathological signs of prion disease were detected in the brains of any of the clinically-
negative mice.
As expected, at the terminal stage of disease high levels of PrPSc were maintained upon
FDC in the Peyer’s patches, MLN and spleen of all clinically-affected mice. However, no evi-
dence of PrPSc accumulation within these lymphoid tissues was observed in any of the orally-
exposed clinically-negative mice (S3 Fig). These data show that all the clinically-negative mice
were free of prions in their lymphoid tissues and brains, and therefore highly unlikely to suc-
cumb clinical prion disease after substantially extended survival times, had the observation
period been extended beyond 525 dpi.
epithelium [22, 35]. A-F) Sections of Peyer’s patches and villous epithelium were stained for the M cell markers GP2
and SPIB. A) Representative distribution of GP2+ (green, mature M cells, upper-panels) and SPIB+ (green, within
the nuclei of differentiating and mature M cells, lower panels) M cells in the Peyer’s patches of mice from each group.
Broken lines indicate the boundary of the FAE. SED, subepithelial dome; V, villi. Morphometric analysis confirmed a
significant increase in the number of (B) GP2+ and (C) SPIB+ M cells in the Peyer’s patches of RANKL-treated mice
(GP2, P<0.0001; SPIB, P<0.001, Student’s t-test; 4–5 FAE/mouse, n = 4 mice/group). D) Morphometric analysis
also revealed a significant increase in the number of GP2+ M cells in the villous epithelium after RANKL-treatment
(P<0.0001, Mann-Whitney U test; 5–7 sections/mouse, n = 4 mice/group). E) Representative distribution of SPIB+
cells (green, arrows) in the villous epithelium of RANKL- and PBS-treated mice. Broken lines indicate the lumenal
surface of the gut epithelium. F) Morphometric analysis confirmed a significant increase in the number of SPIB+ cells
in the villous epithelium after RANKL-treatment (P<0.0001, Mann-Whitney U test; 3–16 sections/mouse, n = 4 mice/
group). G) C57BL/6 mice were treated daily with RANKL (or PBS as a control) to induce M cell-differentiation and on
d 2 orally-gavaged with 2x1011 fluorescent microbeads. Peyer’s patches and intestines were collected 24 h later to
compare the functional ability of M cells in the intestines of mice from each group to acquire and transcytose
particulate antigens. Fluorescent microbeads (green, arrows) were detected in sections of Peyer’s patches (left-
hand panels) and intestine (right panels) by fluorescence microscopy. V, villi; broken line, lumenal surface of the gut
epithelium. In the intestines of RANKL-treated mice the number of fluorescent microbeads in (H) the SED of the
Peyer’s patches (P<0.0001, Mann-Whitney U test; 27 Peyer’s patch sections/mouse, n = 4 mice/group) and (I) villi
(P<0.0001, Mann-Whitney U test; 24 intestine sections/mouse, n = 4 mice/group) was significantly increased. J)
Sections of Peyer’s patches and villi from PBS- and RANKL-treated mice were also immunostained to identify
LAMP1+ endosomes (red) in the epithelium. Broken lines indicate the boundary of the epithelium. K&L)
Morphometric analysis of the % area of LAMP1+ immunostaining in (K) the FAE (1–6 FAE per mouse, n = 4 mice/
group) and (L) villous epithelium (3–14 villi sections per mouse, n = 4 mice/group. DAPI (blue) was used to
counterstain nuclei throughout.
doi:10.1371/journal.ppat.1006075.g006
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Fig 7. Effect of RANKL-treatment on mononuclear phagocytes and innervation in Peyer’s patches and
the lamina propria of the intestine. C57BL/6 mice were treated daily with RANKL (or PBS as a control) to
induce M cell-differentiation and Peyer’s patches and intestines collected on d 3. A) Immunohistochemical
(IHC) comparison of the distribution of CD11c+ (green) and CD68+ (red) mononuclear phagocytes (indicative of
classical DC and tissue macrophages, respectively) in Peyer’s patches of RANKL- and PBS-treated mice.
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Our data suggested that RANKL-treatment significantly increased susceptibility to orally-
administered prions. Indeed, no significant difference in disease incidence or mean survival
time was observed in the RANKL-treated mice exposed to a 0.1% dose of prions when com-
pared to PBS-treated control mice given a 10X higher (1%) dose (PBS/1% vs. RANKL/0.1%,
P = 0.205; Log-rank [Mantel-Cox] test; Fig 8A). Together, these data demonstrate that
increased M cell-deficiency in the gut epithelium following RANKL-treatment significantly
enhances oral prion disease susceptibility by approximately 10-fold. Although certain concur-
rent pathogen infections or inflammatory stimuli may have multiple effects on the gut epithe-
lium, our data suggest that factors such as these that modify M cell-density in the intestine [25,
39, 40] may represent important risk factors which can significantly influence susceptibility to
orally-acquired prion infections.
Increased M cell-density enhances the early accumulation of prions in
lymphoid tissues
Prion replication within Peyer’s patches is essential for efficient neuroinvasion after oral expo-
sure [10–13]. We therefore determined whether the decreased survival times and increased
prion disease susceptibility in orally-exposed RANKL-treated mice were associated with the
earlier accumulation of prions in their lymphoid tissues. Mice were treated with RANKL (or
PBS as a control) and orally exposed to a 1% dose of ME7 scrapie prions as above, and culled
at intervals afterwards (n = 4/group). Abundant accumulations of PrPSc were clearly evident in
association with FDC in the Peyer’s patches, MLN and spleen of RANKL-treated mice by 70
dpi, and were undetectable in the majority of the tissues from the PBS-treated animals at this
time (Fig 9A & 9B). To compare prion infectivity levels between the treatment groups, spleen
homogenates were prepared and injected intracerebrally (i.c.) into groups of tga20 indicator
mice (n = 4/spleen homogenate). As the expression level of PrPC controls the prion disease
incubation period, tga20 mice which overexpress PrPC are extremely useful as indicator mice
in prion infectivity bioassays as they succumb to disease with much shorter survival times than
conventional mice [59]. Significantly high levels of prion infectivity were detected in three of
four of the spleens collected from the RANKL-treated mice at 70 dpi, whereas only one of four
spleens from the PBS treated spleen contained detectable levels of prion infectivity (P<0.0002,
Log-rank [Mantel-Cox] test; Fig 9C). By 105 dpi abundant accumulations of PrPSc were
detected at equivalent frequencies in the lymphoid tissues of the PBS- and RANKL-treated ani-
mals (Fig 9D).
These data show that an increased density of M cells in the intestinal epithelium at the time
of oral exposure enhanced the uptake of prions from the gut lumen, as the RANKL-treated
mice accumulated prions within their lymphoid tissues significantly earlier than control mice.
Sections were counterstained with DAPI (blue) to detect cell nuclei. Broken lines show the lumenal boundary of
the follicle associated epithelium (FAE). SED, subepithelial dome. Morphometric analysis suggested that the %
area of the SED occupied by CD11c+ (B) and CD68+ (C) immunostaining was similar in Peyer’s patches from
each group (CD11c, P = 0.579, Student’s t-test; CD68, P = 0.241, Mann-Whitney U test; 4–8 SED/mouse, n = 4
mice/group). D) IHC comparison of the distribution of CD11c+ (green) and CD68+ (red) mononuclear
phagocytes in the lamina propria (LP) of RANKF/F and RANKΔIEC mice. Sections were counterstained with
DAPI (blue). Morphometric analysis suggested that the % area of (E) CD11c+ immunostaining was similar in
the LP of mice from each group (P = 0.380, Student’s t-test), whereas the % area of (F) CD68+ immunostaining
was increased in the LP of RANKL-treated mice (P < 0.021. Mann-Whitney U test; data derived from 4 LP
areas/mouse, n = 4 mice/group). G) Sections of intestines from RANKL- and PBS-treated mice were
immunostained to identify synaptophysin 1 (red) to enable enteric innervation in the gut wall to be compared in
each treatment group. Sections were counterstained with DAPI (blue). H) Morphometric analysis suggested
that the % area of synaptophysin 1+ immunostaining within the LP was similar (P = 0.078, Student’s t-test; data
derived from 2–4 LP areas/mouse, n = 4 mice/group).
doi:10.1371/journal.ppat.1006075.g007
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Fig 8. RANKL treatment significantly enhances susceptibility to oral prion disease. C57BL/6 mice were treated daily
for 4 d with RANKL (or PBS as a control) to induce M cell-differentiation, and orally-exposed to a moderate (1% scrapie
brain homogenate) or limiting (0.1%) dose of ME7 scrapie prions between the 3rd and 4th treatments. A) RANKL-treatment
significantly increased disease susceptibility following oral exposure to a limiting dose of prions. Clinical prion disease
survival curves for PBS- (solid lines) or RANKL-treated mice (broken lines) orally exposed to either a 1% (blue lines) or
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The effects of RANKL treatment on oral prion disease pathogenesis are
restricted to the intestinal epithelium
Although a rare occurrence in the steady-state, certain pathogenic microorganisms can stimu-
late the direct sampling of the gut lumenal contents by classical DC [60–63]. Whether this
direct sampling activity by classical DC also contributes to the efficient uptake of orally-admin-
istered prions in the steady-state is uncertain [8, 16, 49]. Since RANKL was administered sys-
temically in the current study, it is plausible that this treatment may have stimulated the direct
sampling of the lumenal contents by cells other than M cells such as classical DC. An addi-
tional experiment was performed to test this hypothesis. As shown above, RANKΔIEC mice are
unable to accumulate prions in their Peyer’s patches due to the specific lack of M cells (Fig 5).
Since RANK-deficiency in RANKΔIEC mice is restricted only to intestinal epithelial cells [23],
we reasoned that if the effects of RANKL-treatment on disease pathogenesis were independent
of their effects on M cells, then RANKL-treatment would also facilitate the uptake of prions
into the Peyer’s patches of RANKΔIEC mice. To address this issue, RANKΔIEC mice were treated
with RANKL and orally exposed to a 1% dose of ME7 scrapie prions as in the previous experi-
ment. At 105 dpi Peyer’s patches and MLN were collected and analysed for the presence of
PrPSc as before. As anticipated, abundant accumulations of PrPSc were detected in association
with FDC in the Peyer’s patches and MLN of orally-exposed C57BL/6 wild-type (WT) control
mice by 105 dpi. However, no PrPSc was detected in tissues from RANKL-treated RANKΔIEC
mice (S4 Fig). These data clearly show that RANKL-treatment was unable to restore prion
accumulation in the Peyer’s patches and MLN of RANKΔIEC mice, indicating that the major
effects of RANKL-treatment on oral prion disease pathogenesis were due to effects on M cell-
deficiency in the intestinal epithelium.
Increased M cell-density in the FAE of Peyer’s patches, not the villous
epithelium, is responsible for the increased oral prion disease
susceptibility in RANKL-treated mice
RANKL-treatment stimulates M cell-differentiation within the FAE of the Peyer’s patches and
also in the villous epithelium (Fig 6; [22, 35, 64]). We therefore considered it plausible that the
enhanced prion pathogenesis we observed in RANKL-treated mice was due to the increased
uptake of prions by the M cells induced in the villous epithelium. If RANKL-treatment had
stimulated the uptake of prions predominantly via villous M cells, we reasoned that this would
have facilitated the earlier transport of prions directly to the MLN [65]. An additional experi-
ment was designed to test this hypothesis.
Lymphotoxin-β-deficient (LTβ-/-) mice lack Peyer’s patches and most peripheral lymph
nodes, but retain MLN and the spleen [66]. These mice also lack FDC in their remaining
0.1% (red lines) dose of prions (PBS/1% vs. RANKL/1%, P = 0.120; PBS/0.1% vs. RANKL/0.1%, P<0.0078; PBS/1% vs.
RANKL/0.1%, P = 0.205; Log-rank [Mantel-Cox] test). B) High levels of spongiform pathology (H&E, upper row), heavy
accumulations of PrPd (brown, second row) and disease-specific PrPSc (PET immunoblot, black, third row), reactive
astrocytes expressing GFAP (brown, fourth row) and active microglia expressing Iba1 (brown, bottom row) were detected in
the brains of all orally-exposed mice with clinical prion disease. However, none of these histopathological signs of prion
disease were detected in the brains of any of the clinically-negative mice up to at least 525 d after oral exposure. Clin.,
clinical prion disease status; pos., clinically positive; neg., clinically negative; individual survival times are shown (dpi, days
post infection). Sections were counterstained with haematoxylin to detect cell nuclei (blue). C&D) The severity and
distribution of the spongiform pathology (vacuolation) within each brain was scored on a scale of 1–5 in nine grey matter
areas: G1, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6,
hippocampus; G7, septum; G8, retrosplenial and adjacent motor cortex; G9, cingulate and adjacent motor cortex; Each
point represents the mean vacuolation score ± SD.
doi:10.1371/journal.ppat.1006075.g008
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Fig 9. RANKL-treatment induces the earlier accumulation of prions in lymphoid tissues after oral
exposure. C57BL/6 mice were treated daily for 4 d with RANKL (or PBS as a control) to induce M cell-
differentiation, and orally-exposed to a moderate (1%) dose of ME7 scrapie prions between the 3rd and 4th
treatments. Peyer’s patches, mesenteric lymph nodes (MLN) and spleens were collected at 70 and 105 days
post infection (dpi). A) At 70 dpi, abundant accumulations of PrPSc (PET immunoblot, black, arrows) were
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lymphoid tissues, as constitutive LT-stimulation is essential for their maintenance [67], and
are refractory to oral prion infection [10, 11]. Peyer’s patches-deficient LTβ-/- mice were γ-irra-
diated and reconstituted with LTβ-expressing (WT) bone marrow (termed WT!LTβ-/- mice,
hereinafter) and tissues collected at 2.5 weekly intervals (n = 4 mice/group). Although the for-
mation of FDC networks within the MLN and spleens of WT!LTβ-/- mice is restored by 5 wk
after reconstitution (Fig 10A), WT!LTβ-/- mice remain refractory to oral prion disease [11]
as Peyer’s patches, not the MLN, are the essential early sites of prion accumulation and neu-
roinvasion after oral exposure [11, 13].
The reconstitution of LTβ-/- mice with WT bone marrow also induces the differentiation
and maturation of isolated lymphoid follicles (ILF) throughout the small intestine [11, 68, 69].
Mature ILF characteristically contain a single organized B cell-follicle, a network of FDC, and
an M cell-containing FAE at the lumenal surface [11, 13, 68]. Since we have shown that mature
small intestinal ILF are important sites of prion accumulation and neuroinvasion [11, 13], it
was necessary to ensure there were no ILF with M cell-containing FAE in the intestines of
WT!LTβ-/- mice at the time of RANKL-treatment and prion exposure. Whole-mount immu-
nostaining of three individual 2 cm sections of small intestine from each WT! LTβ-/- mouse
showed that ILF with developed FAE containing GP2+ M cells were not present until 12.5
post-reconstitution (Fig 10B & 10C). These data revealed a window of opportunity between
5–10 wk post-reconstitution during which the small intestines of WT!LTβ-/- mice lacked
FAE and M cell-containing GALT, but possessed FDC within their MLN. This FAE-deficient
model was therefore used to determine whether RANKL-treatment facilitated the direct deliv-
ery of prions from the gut lumen to the MLN.
At 7.5 wk post-reconstitution WT!LTβ-/- mice (n = 3-4/group) were treated with RANKL
(or PBS as a control) for 4 d and orally-exposed to prions as before, and prion infectivity levels
determined in their MLN 28 d later. Tissues were assayed for prion infectivity at this time after
oral exposure to determine whether RANKL-treatment of WT!LTβ-/- mice facilitated the ear-
lier replication of prions within the MLN. Consistent with our previous data showing that
Peyer’s patches in the small intestine, not the MLN, are the important early sites of prion accu-
mulation after oral exposure [11, 13], prion infectivity was undetectable in the MLN of the
PBS control-treated WT!LTβ-/- mice. Similarly, prion infectivity was also undetectable in the
MLN of the RANKL-treated WT!LTβ-/- mice. In each instance all the recipient tga20 indica-
tor mice (n = 4/MLN homogenate tested) were free of clinical disease up to 200 dpi (Fig 10D)
and had no histopathological signs of prion disease in their brains (spongiform pathology and
PrPd deposition; Fig 10E). These data clearly show that RANKL-treatment did not stimulate
the early transport of prions directly to the MLN. This suggests that the enhanced prion disease
pathogenesis observed in RANKL-treated mice was due to the increased uptake of prions from
the gut lumen by M cells in the FAE of the Peyer’s patches, rather than by villous M cells.
clearly evident in association with FDC (CD21/35+ cells, brown, arrows) in the Peyer’s patches, MLN and
spleens of many of the RANKL-treated mice, but were undetectable in the majority of the tissues from the PBS-
treated mice. Sections were counterstained with haematoxylin to detect cell nuclei (blue). B) At 70 dpi, the
frequency of FDC networks containing PrPSc was increased in the Peyer’s patches, MLN and spleens of the
RANKL-treated mice when compared to PBS-treated control mice (n = 4 mice/group). C) Prion infectivity levels
were assayed in spleens from RANKL-treated and PBS-treated control mice (n = 4 spleens/group) collected at
70 dpi. Prion infectivity titres (log10 ID50/g tissue) were determined by injection of tissue homogenates into
groups of tga20 indicator mice (n = 4 recipient mice/spleen). Each symbol represents data derived from an
individual spleen. Data below the horizontal line indicate disease incidence in the recipient mice <100% and
considered to contain trace levels of prion infectivity. D) At 105 dpi, no difference in the frequency of FDC
networks containing PrPSc was observed in the Peyer’s patches, MLN and spleens of mice from each
treatment group (n = 4 mice/group).
doi:10.1371/journal.ppat.1006075.g009
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Fig 10. Villous M cells induced by RANKL-treatment do not enhance the transport prions to the mesenteric lymph
nodes (MLN). This experiment aimed to determine whether the enhanced prion pathogenesis we observed in RANKL-
treated C57BL/6 mice wild-type (WT) mice was due to the increased uptake of prions by the M cells induced in the villous
epithelium. A mouse model was created in which their small intestines lacked follicle associated epithelia (FAE) and M cell-
containing gut-associated lymphoid tissues, but possessed follicular dendritic cells (FDC) in their MLN. A-C) Peyer’s
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Discussion
Here we show that the density of M cells in the gut epithelium directly influences oral prion
disease pathogenesis and susceptibility. In the specific absence of M cells, the accumulation of
prions in Peyer’s patches and subsequent neuroinvasion was blocked, demonstrating that
prion translocation across the gut epithelium in association with M cells is essential to establish
host infection. Our data also imply that an absence or reduction in M cell-abundance may sig-
nificantly reduce susceptibility to many naturally acquired prion diseases such as vCJD in
humans, CWD in cervids and natural sheep scrapie. For example, in the UK most clinical
vCJD cases have predominantly occurred in young adults (median age at death, ~28 years) [4],
but epidemiological data indicate that this age-related susceptibility is not simply due to the
exposure of young individuals to greater levels of the BSE agent through dietary preference
[70]. We have previously shown that the density of functionally mature M cells in the Peyer’s
patches of aged mice is substantially reduced [71], suggesting that the reduced susceptibility of
aged mice to oral prion infection [72] is at least in part due to the inefficient uptake of prions
from the gut lumen by M cells.
We also show that increased M-cell density at the time of oral exposure exacerbated prion
disease pathogenesis: the uptake of prions from the gut lumen was enhanced, and as a conse-
quence, survival times were decreased and disease susceptibility was increased approximately
10-fold. The density of M cells in the gut epithelium can be modified by the presence of certain
pathogenic bacteria or inflammatory stimuli [25, 39, 40]. Although these stimuli may have
multiple effects on the gut epithelium which can influence the integrity of this barrier, data in
the current study provide a significant advance in our understanding of how factors that
increase the density of M cells in the gut epithelium may increase susceptibility to orally-
acquired prion infection. For example, the enteroinvasive bacterium Salmonella Typhimurium
can specifically and rapidly transform enterocytes in the FAE of Peyer’s patches into M cells in
order to facilitate host infection [25]. Furthermore, an independent study has shown that con-
current infection with S. Typhimurium significantly increased oral prion disease susceptibility
[43]. Although this observation was originally attributed to the colitis induced by the pathogen
in the large intestine, data in the current study suggest a role for effects on M cells in the small
intestine cannot be excluded.
patches-deficient LTβ-/- mice were γ-irradiated and reconstituted with WT bone marrow (WT!LTβ-/- mice) and tissues from
3–4 mice examined at intervals afterwards. LTβ-/- mice and WT mice were included as controls. A) Immunohistochemical
analysis revealed that the development of FDC (CD35+ cells, red) in the B cell-follicles (B220+ cells, green) of MLN (upper
panels) and spleens of WT!LTβ-/- mice was restored by 5 wk after bone-marrow reconstitution. Images are representative
of 3–4 mice/group. B) Beginning at 5 wk post-reconstitution, and at 2.5 wk intervals thereafter, 3 individual 2 cm pieces of
intestine/mouse were whole-mount immunostained to detect M cells (GP2+ cells, green) and goblet cells (UEA-1+ cells, red).
F-actin (blue) was used as a counterstain. Characteristic epithelial structures that contained GP2+ M cells and resembled
the FAE covering isolated lymphoid follicles were absent in the intestines of LTβ-/- mice (left-hand panels) but were
detectable from 12.5 wk post-reconstitution in WT!LTβ-/- mice. FAE highlighted by broken lines in WT!LTβ-/- panels. The
broken line in the upper right-hand WT panel highlights 6 individual FAE covering a Peyer’s patch. Images are
representative of 3–4 mice/group. C) The total no. FAE across the 3 individual 2 cm intestinal pieces were counted (n = 3–4
mice/group). D) WT!LTβ-/- mice were prepared as above and at 7.5 wk post reconstitution (when FDC present but FAE
absent) were treated with RANKL for 4 d (or PBS as a control) to induce the differentiation of villous M cells in the intestine.
Between the 3rd and 4th treatments, the mice were subsequently orally-exposed to a 1% dose of ME7 scrapie prions, and
MLN were collected 28 d later (n = 3–4 MLN/group). Prion infectivity titres (log10 ID50/g tissue) were determined by injection
of MLN tissue homogenates into groups of 4 tga20 indicator mice. Each symbol represents data derived from an individual
MLN. Data below the horizontal line indicate disease incidence in the recipient mice <100% and considered to contain trace
levels of prion infectivity. E) Confirmation that none of the brains from the clinically-negative tga20 indicator mice injected
with MLN from PBS- or RANKL-treated donors contained histopathological signs of prion disease at the end of the
experiment (200 d post-injection): spongiform pathology (H&E, upper panels), or PrPd deposition (lower panels). Sections
were counterstained with haematoxylin to detect cell nuclei (blue). Images are representative of 12–16 mice/group.
doi:10.1371/journal.ppat.1006075.g010
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During the BSE epidemic in the UK it is estimated that approximately 500,000 infected cat-
tle were slaughtered for human consumption [73]. Despite the widespread dietary exposure of
the UK human population to BSE prions, clinical cases of vCJD have fortunately been rare
(Ref. [4]; 178 definite or probable cases, as of 5th December 2016; www.cjd.ed.ac.uk/
documents/figs.pdf). This implies that the ability to acquire prions from the gut lumen may
differ between individuals. Studies using transgenic mice expressing human PrPC suggest that
the transmission of BSE to humans is restricted by a significant species barrier [74]. After inter-
species prion exposure, the processing and amplification of prions upon FDC in lymphoid tis-
sues is important for their adaptation to the new host and to achieve neuroinvasion [75, 76].
Thus, it is plausible that factors which increase the density of M cells in the small intestine may
enable a greater burden of prions to enter Peyer’s patches, increasing the probability that more
will be able to avoid clearance by cells such as macrophages, [11, 77]. This may provide a
greater opportunity for prion quasi-species present within the original inoculum with zoonotic
potential to be selected and undergo adaptation and amplification upon FDC [78]. These
effects may help to reduce the transmission barrier to some orally acquired prion strains.
Enterocytes within the FAE overlying the Peyer’s patches specifically contain large
LAMP1+ endosomes [16]. A detailed high resolution IHC-based study has shown that within
the first day following oral exposure of mice to prions, PrPSc was detected within these large
LAMP1+ endosomes of FAE enterocytes, and to a lesser extent in M cells [16]. These FAE
enterocyte-associated endosomes have been proposed as a potential M cell-independent route
through which lumenal proteins and prions may also be taken up into Peyer’s patches [16]. In
the current study the presence and abundance of the large LAMP1+ endosomes within FAE
enterocytes was unaffected in M cell-deficient RANKΔIEC mice. These data clearly show that
the specific lack of M cells in the FAE, rather than an absence of the large LAMP1+ endosomes
within FAE enterocytes, was responsible for the blocked prion accumulation in Peyer’s
patches. Furthermore, the accumulation of prions in the Peyer’s patches, MLN and spleens of
orally-exposed M cell-deficient RANKΔIEC mice was undetectable up to at least 440 d after
exposure. As abundant prion accumulation is typically evident in these tissues in conventional
(WT) mice by 105 d after exposure, this implies that in the absence of M cells, any prions that
do enter the Peyer’s patches via alternative routes may be of insufficient magnitude to establish
infection. Indeed PrPSc was also undetectable in the lymphoid tissues and CNS of these mice
up to at least 440 dpi. Instead the prions that are acquired from the gut lumen by these M cell-
independent routes are most likely sequestered and destroyed by cells such as macrophages,
which are considered to degrade prions [77], rather than being efficiently transported to FDC
where they undergo amplification before neuroinvasion [7, 10, 13, 15]. RANKΔIEC mice show
reduced IgA production and delayed germinal centre responses in their Peyer’s patches [23].
This suggests that antigens that are transcytosed by M cells are preferentially targeted to the
FDC-containing B-cell follicles to initiate antibody responses. Therefore, M cells, in contrast
to FAE enterocytes with large LAMP1+ endosomes, may be considered to facilitate the efficient
transfer of prions from the gut lumen to FDC in the B-cell follicles of Peyer’s patches.
A separate IHC-based study also has proposed that the uptake of scrapie-affected brain
homogenate across the jejunal epithelium of lambs occurs independently of M cells [34]. How-
ever, if prions do efficiently establish infection within Peyer’s patches after their translocation
across the gut epithelium by enterocytes, one would not expect the specific absence of M cells
in RANKΔIEC mice to block oral prion disease susceptibility. In the above in vivo study [34],
large quantities of scrapie-affected brain homogenate were injected directly into the lumen of
ligated loops of jejunum. The presence of a large bolus of prions concentrated within the
lumen of these ligated loops may have facilitated prion uptake into alternative cellular com-
partments to those utilized following exposure to physiologically relevant doses via the oral
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cavity. Although evidence of prions (PrPd) was detected in the underlying LP of these lambs, it
was interesting to note that no intraepithelial PrPd accumulations were detected by IHC [34].
Whether the prions were transiently present in enterocytes and/or M cells soon after exposure,
but at levels below the reliable detection limit or in a conformation which could not be
detected by the IHC protocols used, remains to be determined. By comparison, in the study by
Kujala and colleagues discussed above [16], PrPSc was detected within the FAE during the first
day after oral exposure using highly sensitive cryo-immunogold electron microscopy. M cells
unlike the neighbouring enterocytes have a very narrow cytoplasm due to the presence of the
MNP-containing basolateral pocket [20]. Thus it is also plausible that the prion transit time
through M cells may be extremely rapid, restricting the ability of IHC to reliably detect low lev-
els of prions or other particles which are being transcytosed through them. Surgical manipula-
tion and manual compression of the intestine can temporarily inhibit intestinal motility and
induce intestinal inflammation with activation of resident macrophages, as occurs during post-
operative ileus [79, 80]. These factors may have a significant influence on the uptake of prions
from the lumen of surgically-ligated intestinal loops.
Using extremely sensitive PrPSc-based detection assays, two independent studies reported
the presence of low/trace levels of prions in the blood-stream within minutes of oral exposure
[81, 82]. The cellular route through which the prions initially gained access to the blood-stream
was not determined in these studies. Urayama and colleagues [82] suggested that the levels of
PrPSc that initially contaminated the blood-stream after oral exposure were sufficient to initiate
infection in the brain. However, data from several studies show that prion replication upon
FDC in Peyer’s patches in the small intestine is essential to establish host infection after oral
exposure [7, 8, 10–13]. Furthermore, in the temporary absence of FDC at the time of oral expo-
sure, prion disease susceptibility is blocked [6]. Thus although PrPSc may be detected in the
blood-stream soon after oral exposure using highly sensitive assays [81, 82], data elsewhere
indicate that the levels of prions that are initially within it are unable to directly establish host
infection and achieve neuroinvasion.
After uptake by M cells, CD11c+ classical DC are considered to deliver prions towards
FDC, as their transient depletion reduces susceptibly to oral prion disease [8]. A partial reduc-
tion in CD11c+ immunostaining was observed in the SED of Peyer’s patches from RANKΔIEC
mice, implying a partial reduction in the abundance of these cells. M cells specifically express
the chemokine CCL9 [22] which mediates the attraction of certain classical DC populations
towards the FAE [83]. Thus, the reduced CD11c+ immunostaining in the SED of RANKΔIEC
mice may be a consequence of the absence of attraction of CD11c+ cells towards the basolateral
pockets of M cells. This partial reduction in CD11c+ immunostaining in SED region alone
could not account for the complete block of prion accumulation observed in RANKΔIEC mice,
as our previous data show that the depletion of CD11c+ cells (>85%) prior to oral exposure
does not block neuroinvasion [8]. Although the germinal centre response is delayed in RAN-
KΔIEC mice [23], our data suggested that FDC status was unaffected in these mice. Further-
more, the FDC in the Peyer’s patches, MLN and spleen of these mice were capable of
accumulating high levels of PrPSc after injection of prions by the i.p. route. We have also previ-
ously shown that an absence of germinal centres themselves does not influence peripheral
prion disease pathogenesis [84].
The GALT in the small intestine such as the Peyer’s patches, not those in the large intestine,
are the major early sites of prion uptake, replication and neuroinvasion after oral exposure [11,
13, 16]. RANKL-RANK signalling is also necessary for the induction of M cell-differentiation
within the large intestine, but in contrast to its role in the small intestine, it does not induce
their maturation. As a consequence, GP2-expressing functionally mature M cells are scarce in
the FAE overlying the large intestinal GALT [64]. Consistent with this, systemic RANKL-
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treatment also does not increase the abundance of functionally mature M cells in the FAE
overlying the caecal patches or in the conventional epithelium of large intestine [64]. These
data suggest that the effects of systemic RANKL-treatment on oral prion disease pathogenesis
observed in the current study were due to an increased abundance of mature M cells specifi-
cally in the small intestine.
In the steady state, functionally mature M cells are confined to the FAE overlying the
Peyer’s patches and are extremely rare within the villous epithelium. However, systemic
RANKL-treatment, as used here, significantly increases the abundance of mature M cells in
the FAE overlying Peyer’s patches and throughout the villous epithelium [22, 35, 64]. There-
fore, it is plausible that the effects of systemic RANKL-treatment on oral prion disease patho-
genesis were in part due to the enhanced uptake of prions by villous M cells, facilitating their
more efficient delivery to the MLN. Using LTβ-/- mice reconstituted with WT bone marrow
(WT!LTβ-/- mice), we generated mice that lacked Peyer’s patches or other M cell-containing
GALT structures (ILF) in their small intestines, but retained MLN which contained mature
FDC. If the major effect of RANKL-treatment on oral prion pathogenesis was due to uptake by
villous M cells and enhanced delivery from the LP to the MLN, the accumulation of prions in
the MLN would likewise be enhanced in these mice after RANKL-treatment. However, our
data clearly show that RANKL-treatment did not enhance the accumulation of prions within
the MLN of WT!LTβ-/- mice. This demonstrates that the major effect of RANKL-treatment
on oral prion disease pathogenesis and susceptibility was due to the increased uptake of prions
across the FAE overlying the Peyer’s patches in the small intestine. The absence of detectable
levels of prion infectivity in the MLN at the time of analysis suggests that any low levels of pri-
ons that do reach this tissue immediately after oral exposure are either not delivered to FDC in
the MLN as efficiently as they are in the Peyer’s patches, or are of insufficient magnitude to
establish infection on FDC and are thus most likely degraded by macrophages [11, 77]. Our
IHC analysis implied that the abundance of CD68+ macrophages was increased in the LP after
RANKL-treatment, suggesting that it is also plausible that any prions that had been acquired
by villous M cells were subsequently sequestered and destroyed in the LP by macrophages.
Classical DC in the LP of the intestine are considered to deliver lumenal antigens directly to
MLN [65]. Here, RANKL-treatment of RANKΔIEC mice did not restore prion accumulation in
their Peyer’s patches and MLN following oral exposure, demonstrating that RANKL-treatment
did not alter the uptake of prions from the gut lumen by non-epithelial cells, such as classical
DC. Our data suggest that direct sampling of the lumenal contents by classical DC in the LP
[60–63] is also unlikely to contribute significantly to prion uptake from the gut lumen, as this
too would result in the direct delivery of prions to the MLN [65].
In conclusion, we show that the initial uptake and transfer of prions across the gut epithe-
lium in association with M cells is essential to establish host infection. Importantly, we also
demonstrate that the density of M cells in the FAE overlying the Peyer’s patches in the small
intestine directly controls the efficiency of oral prion infection. In the specific absence of M
cells, the uptake and accumulation of prions in Peyer’s patches and their subsequent spread to
the MLN and spleen is blocked. In contrast, oral prion disease susceptibility was enhanced
approximately 10-fold in mice in which M cell-deficiency in the gut epithelium was increased.
Thus, M cells could be considered as the gatekeepers of oral prion infection whose density
directly limits or enhances disease susceptibility. Further studies are necessary to determine
whether most orally acquired prion strains similarly exploit intestinal M cells to establish host
infection after oral exposure, but data from independent in vivo and in vitro studies using
mouse-passaged RML scrapie prions [30], Fukuoka-1 prions [31], BSE prions [32] and 263K
hamster prions [17] imply a similar requirement. Antigen sampling M cells are also present in
the FAE overlying the NALT in the nasal cavity [44, 45], but data from the analysis of prion
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disease pathogenesis in hamsters implies that the requirement for M cell-mediated uptake may
vary depending on the route of exposure [85]. After intra-nasal exposure some transient
uptake of 263K prions was observed in M cells within the FAE overlying the NALT, but a
greater magnitude of paracellular transport across the epithelia within the nasal cavity was also
noted [85]. Although certain concurrent pathogen infections, inflammatory stimuli and aging
may have multiple effects on the gut epithelium, our data suggest that factors such as these that
can modify M cell-density in the small intestine [25, 39, 40, 71] may represent important risk
factors which can significantly influence susceptibility to orally-acquired prion infections. Our
data also raise the possibility that the density of M cells in the gut epithelium may similarly
influence susceptibility to other important orally-acquired bacterial and viral pathogens which
are considered to exploit M cells to infect the host [24–28].
Materials and Methods
Ethics statement
All studies using experimental mice and regulatory licences were approved by both The Roslin
Institute’s and University of Edinburgh’s ethics committees. All animal experiments were car-
ried out under the authority of a UK Home Office Project Licence (PPL60/4325) within the
terms and conditions of the strict regulations of the UK Home Office ‘Animals (scientific pro-
cedures) Act 1986’. Where necessary, anaesthesia appropriate for the procedure was adminis-
tered, and all efforts were made to minimize harm and suffering. Mice were humanely culled
by a UK Home Office Schedule One method.
Mice
The following mouse strains were used in this study where indicated: C57BL/6J; Villin-cre (Tg
(Vil-cre)997Gum/J strain; The Jackson Laboratory, Bar Harbor, ME); RANKfl/fl, which have
loxP sites flanking exons 2 and 3 of Tnfrsf11a (which encodes RANK) [23]; LTβ-/- [86]; tga20,
which overexpress PrPC [59]. All mice were bred and maintained on a C57BL/6J background
and housed under SPF conditions.
γ-Irradiation and bone-marrow reconstitution
Bone-marrow from the femurs and tibias of donor mice was prepared as single-cell suspen-
sions (3x107–4x107 viable cells/ml) in HBSS (Life Technologies, Paisley, UK). Recipient adult
LTβ-/- mice (6–8 weeks old) were γ-irradiated (10 Gy) and 24 h later reconstituted with 100 μl
bone-marrow by injection into the tail vein.
Recombinant mouse RANKL
Glutathione S-transferase—RANKL fusion protein was prepared as described [35]. To
enhance M-cell-density in the gut epithelium mice were treated with RANKL in vivo as previ-
ously described [22, 35]: d 0 injected with RANKL by a combination of i.p. and subcutaneous
injection (50 μg/ea.); d 1, 50 μg RANKL by subcutaneous injection; d 2, 50 μg RANKL by sub-
cutaneous injection; d 3, 50 μg RANKL by subcutaneous injection. Mice were orally exposed
to prions or gavaged with fluorescent microbeads on d 2 after the onset of RANKL treatment.
Prion exposure and disease monitoring
For oral exposure, mice were fed individual food pellets doused with 50 μl of a 1% (containing
approximately 2.5 X 104 i.c. ID50 units) or 0.1% (w/v) dilution of scrapie brain homogenate
prepared from mice terminally-affected with ME7 scrapie prions according to our standard
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protocol [7–9, 11, 13, 72]. During the dosing period mice were individually housed in bedding-
and food-free cages. Water was provided ad libitum. A single prion-dosed food pellet was then
placed in the cage. The mice were returned to their original cages (with bedding and food ad
libitum) as soon as the food pellet was observed to have been completely ingested. The use of
bedding- and additional food-free cages ensured easy monitoring of consumption of the
prion-contaminated food pellet. For i.p. exposure, mice were injected with 20 μl of a 1% dilu-
tion of scrapie brain homogenate. Following prion exposure, mice were coded and assessed
weekly for signs of clinical disease and culled at a standard clinical endpoint. The clinical end-
point of disease was determined by rating the severity of clinical signs of prion disease exhib-
ited by the mice. Following clinical assessment, mice were scored as “unaffected”, “possibly
affected” and “definitely affected” using standard criteria which typically present in mice clini-
cally-affected with ME7 scrapie prions. Clinical signs following infection with the ME7 scrapie
agent may include: weight-loss, starry coat, hunched, jumpy behaviour (at early onset) pro-
gressing to limited movement, upright tail, wet genitals, decreased awareness, discharge from
eyes/blinking eyes, ataxia of hind legs. The clinical endpoint of disease was defined in one of
the following ways: i) the day on which a mouse received a second consecutive “definite” rat-
ing; ii) the day on which a mouse received a third “definite” rating within four consecutive
weeks; iii) the day on which a mouse was culled in extremis. Survival times were recorded for
mice that did not develop clinical signs of disease or were culled when they showed signs of
intercurrent disease. Prion diagnosis was confirmed by histopathological assessment of vacuo-
lation in the brain. For the construction of lesion profiles, vacuolar changes were scored in
nine distinct grey-matter regions of the brain as described [87].
For bioassay of prion infectivity individual MLN or spleen were prepared as 1% (wt/vol)
homogenates in physiological saline. For each tissue homogenate groups of tga20 indicator
mice (n = 4/homogenate) were injected i.c. with 20 μl of each homogenate. The prion infectiv-
ity titre in each sample was determined from the mean incubation period in the indicator
mice, by reference to a dose/incubation period response curve for ME7 scrapie-infected spleen
tissue serially titrated in tga20 mice using the relationship: y = 9.4533–0.0595x (where y is log
ID50 U/20 μl of homogenate, and x is the incubation period; R2 = 0.9562).
IHC and immunofluorescent analyses
Whole-mount immunostaining was performed as previously described [9]. Peyer’s patches,
NALT and pieces of small intestines were fixed with BD Cytofix/Cytoperm (BD Biosciences,
Oxford, UK), and subsequently immunostained with rat anti-mouse GP2 mAb (MBL Interna-
tional, Woburn, MA; 5 μg/ml). Following addition of primary Ab, tissues were stained with
Alexa Fluor 488-conjugated anti-rat IgG Ab (Life Technologies), rhodamine-conjugated Ulex
europaeus agglutinin I (UEA-1; Vector Laboratories Inc., Burlingame, CA; 20 μg/ml) and
Alexa Fluor 647-conjugated phalloidin to detect f-actin (Life Technologies; 4 U/ml).
Intestines, MLNs and spleens were also removed and snap-frozen at the temperature of liq-
uid nitrogen. Serial frozen sections (6 μm in thickness) were cut on a cryostat and immunos-
tained with the following antibodies: FDC were visualized by staining with mAb 7G6 to detect
CR2/CR1 (CD21/35; BD Biosciences; 1 μg/ml) or mAb 8C12 to detect CR1 (CD35; BD Biosci-
ences; 1.25 μg/ml); cellular PrPC was detected using PrP-specific polyclonal antibody (pAb)
1B3 [88] (1/1000 dilution); B cells were detected using rat anti-mouse B220 mAb (clone RA3-
6B2, Life Technologies; 5 μg/ml); MNP were detected using hamster anti-mouse CD11c mAb
(clone N418, Bio-Rad, Kidlington, UK; 5 μg/ml) or rat anti-mouse CD68 mAb (clone FA-11,
Biolegend, Cambridge, UK; 5 μg/ml); rat anti-mouse CD107a (clone 1D4B; Biolegend;
2.5 μg/ml) to detect LAMP1; nerve synapses were detected using rabbit anti-synaptophysin 1
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(Synaptic Systems, Go¨ttingen, Germany; 1/150 dilution). For the detection of SPIB in parafor-
maldehyde-fixed sections, antigen retrieval was performed with citrate buffer (pH 7.0, 121˚C,
5 min.) prior to immunostaining with sheep anti-mouse SPIB polyclonal antibody (R&D Sys-
tems, Abingdon, UK; 0.4 μg/ml). Appropriate species and immunoglobulin isotype control Ab
were used as controls (S5 Fig). Where appropriate, sections were counter-stained with DAPI
(2.86 μM) to detect cell nuclei (Life Technologies).
For the detection of disease-specific PrP (PrPd) in intestines, MLN, spleens and brains, tis-
sues were fixed in periodate-lysine-paraformaldehyde fixative and embedded in paraffin wax.
Sections (thickness, 6 μm) were deparaffinised, and pre-treated to enhance the detection of
PrPd by hydrated autoclaving (15 min, 121˚C, hydration) and subsequent immersion formic
acid (98%) for 10 min. Sections were then immunostained with 1B3 PrP-specific pAb (1/1000
dilution). For the detection of astrocytes, brain sections were immunostained with anti-glial
fibrillary acidic protein (GFAP; DAKO, Ely, UK; 1/400 dilution). For the detection of micro-
glia, deparaffinised brain sections were first pre-treated with citrate buffer and subsequently
immunostained with anti-ionized calcium-binding adaptor molecule 1 (Iba1; Wako Chemicals
GmbH, Neuss, Germany; 0.5 μg/ml). For the detection of FDC in intestines, MLN and spleens,
deparaffinised sections were first pre-treated with Target Retrieval Solution (DAKO) and sub-
sequently immunostained with anti-CD21/35 mAb. PET immunoblot analysis was used to
confirm the PrPd detected by immunohistochemistry was proteinase K-resistant PrPSc [57].
Membranes were subsequently immunostained with 1B3 PrP-specific pAb (1/4000 dilution).
For light microscopy, following the addition of primary antibodies, biotin-conjugated spe-
cies-specific secondary antibodies (Stratech, Soham, UK) were applied and immunolabelling
was revealed using HRP-conjugated to the avidin-biotin complex (ABC kit, Vector Laborato-
ries) and visualized with DAB (Sigma, Dorset, UK). Sections were counterstained with haema-
toxylin to distinguish cell nuclei. For fluorescent microscopy, following the addition of
primary antibody, streptavidin-conjugated or species-specific secondary antibodies coupled to
Alexa Fluor 488 (green), Alexa Fluor 594 (red) or Alexa Fluor 647 (blue) dyes (Life Technolo-
gies) were used. Sections were counterstained with either DAPI or Alexa Fluor 647-conjugated
phalloidin and subsequently mounted in fluorescent mounting medium (DAKO). Images of
whole-mount immunostained tissues and cryosections were obtained using a Zeiss LSM710
confocal microscope (Zeiss, Welwyn Garden City, UK).
Image analysis
For morphometric analysis, images were analysed using ImageJ software (http://rsb.info.nih.
gov/ij/) as described on coded sections [89]. Background intensity thresholds were first applied
using an ImageJ macro which measures pixel intensity across all immunostained and non-
stained areas of the images. The obtained pixel intensity threshold value was then applied in all
subsequent analyses. Next, the number of pixels of each colour (black, red, green, yellow etc.)
were automatically counted. For these analyses, data are presented as the proportion of posi-
tively-stained pixels for a given IHC marker per total number of pixels (all colours) in the spe-
cific area of interest (eg: SED, FAE, LP etc.). In each instance, typically 3–6 images were
analysed per mouse, from tissues from multiple mice per group (n = 4–8 mice/group). Full
details of all the sample sizes for each parameter analysed are provided in every figure legend.
Oral gavage with fluorescent microbeads
Mice were given a single oral gavage of 2x1011 of Fluoresbrite Yellow Green labelled 200 nm
microbeads (Polysciences, Eppelheim, Germany) in 200 μl PBS. Mice were culled 24 h later
and Peyer’s patches and small intestine segments were snap-frozen at the temperature of liquid
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nitrogen. Serial frozen sections (6 μm in thickness) were cut on a cryostat and counterstained
with DAPI. Images of SED from three Peyer’s Patches (duodenal, jejunal and ileal) and 8 LP
areas per mouse (n = 3–4 mice/group) from 3 non-sequential sections (total 21–31 SED, or 24
LP areas per mouse studied) were typically acquired using a Nikon Eclipse E400 fluorescent
microscope using Micro Manager (http://www.micro-manager.org). For example, each Peyer’s
patch was trimmed until at least one SED region was visible and 20 sections collected. The 1st,
10th and 20th sections were then analysed. Tissue auto-fluorescence was subtracted from dis-
played images using ImageJ, the size of the area of interest in each section was then measured
and the number of beads determined using the cell counter function in ImageJ and the bead
density calculated.
In vitro enteroid cultivation
Intestinal crypts were dissociated from mouse small intestine using Gentle Cell Dissociation
Reagent (Stemcell Tech, Cambridge, UK) and used establish enteroids by cultivation in Matri-
gel (BD Bioscience) and Intesticult medium (Stemcell Tech) as described [23, 90]. Where indi-
cated, some wells were treated with RANKL (100 ng/ml). Enteroids were cultivated in
triplicate and either passaged after 5 d of cultivation [90] or harvested for mRNA expression
analysis as described [23].
Real-time quantitative PCR (RT-qPCR) analysis of mRNA expression
Total RNA was isolated from the enteroid cultures using RNA-Bee (AMS Biotechnology,
Oxfordshire, UK) followed by treatment with DNase I (Ambion, Warrington, UK). First
strand cDNA synthesis was performed using 1 μg of total RNA and the First Strand cDNA
Synthesis kit (GE Healthcare, Bucks, UK) as described by the manufacturer. PCR was per-
formed using the Platinum-SYBR Green qPCR SuperMix-UDG kit (Life Technologies) and
the Stratagene Mx3000P real-time qPCR system (Stratagene, CA, USA). The qPCR primers
(S1 Table) were designed using Primer3 software [91]. The cycle threshold values were deter-
mined using MxPro software (Stratagene) and normalized relative to Gapdh.
Statistical analyses
All data are presented as mean ± SD. Unless indicated otherwise, differences between groups
were analysed by a Student’s t-test. In instances where there was evidence of non-normality
(identified by the Kolmogorov-Smirnov, D’Agostino & Pearson omnibus, or Shapiro-Wilk
normality tests), data were analysed by a Mann-Whitney U test. Survival rates were analysed
using the Log-rank (Mantel-Cox) test. Values of P<0.05 were accepted as significant.
Supporting Information
S1 Table. Primers used for RT-qPCR analysis.
(DOCX)
S1 Fig. RANKL-treatment induces the expression of M cell-related genes in in vitro culti-
vated enteroids. Enteroids were prepared from the small intestines of RANKF/F and RAN-
KΔIEC mice. Following passage the enteroids were treated with either RANKL (100 ng) or PBS
as a control. The expression of (A) M cell, (B) Paneth cell, and (C) intestinal stem cell-related
genes was compared 7 d after treatment (n = 3 enteroid cultures/group). Gene expression was
determined by RT-qPCR and normalized to the expression level of Gapdh (mean ± SD).
(TIF)
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S2 Fig. Effect of RANKL-treatment follicular dendritic cell (FDC) status. Immunohisto-
chemical (IHC) and morphometric analyses were used to determine whether RANKL-treat-
ment influenced the status of follicular dendritic cells (FDC) in Peyer’s patches and mesenteric
lymph nodes (MLN). C57BL/6 mice were treated daily with RANKL (or PBS as a control) to
induce M cell-differentiation, and Peyer’s patches, intestines and MLN collected on d 3. A)
IHC comparison of CD21/35 (red) and PrPC (blue) expression by FDC in the B cell-follicles
(B220+ cells, green) of Peyer’s patches from RANKL- and PBS-treated mice. B) Morphometric
analysis suggested that the area of the CD21/35+ immunostaining in the Peyer’s patches of
mice from each treatment group was similar (P = 0.104, Student’s t-test; data derived from 3–4
follicles/mouse, n = 4 mice/group). C) Morphometric analysis suggested that the % area of
PrPC immunostaining within the CD21/35+ FDC networks was also similar in Peyer’s patches
of mice from each treatment group (P = 0.485, Mann-Whitney U test; data derived from 2–8
follicles/mouse, n = 3 mice/group). D) Sections of MLN from RANKL- and PBS-treated mice
were immunostained to detect B cells (B220, green), FDC (CD21/35+ cells, red) and PrPC
(blue). E) Morphometric analysis similarly suggested that the % area of PrPC immunostaining
within the FDC networks was equivalent in the MLN from RANKL- and PBS-treated mice
(P = 0.065, Mann-Whitney U test; data derived from 2–6 follicles/mouse, n = 4 mice/group).
(TIF)
S3 Fig. Prion accumulation in the lymphoid tissues of PBS- and RANKL-treated mice at
the terminal stage of disease. C57BL/6 mice were treated daily for 4 d with RANKL (or PBS
as a control) to induce M cell-differentiation, and orally-exposed to a limiting (0.1%) dose of
ME7 scrapie prions between the 3rd and 4th treatments. Peyer’s patches, mesenteric lymph
nodes (MLN) and spleen were collected from all clinically-affected mice and those which were
free of the clinical signs of prion disease at the end of the experiment at 525 days post infection
(dpi). Clin., clinical prion disease status; pos., clinically positive; neg. clinically negative; indi-
vidual survival times are shown. High levels of PrPSc (PET immunoblot, black, arrows) were
detected in association with follicular dendritic cells (CD21/35+ cells, brown, arrows) in the
Peyer’s patches, MLN and spleens from all clinically-affected mice. In contrast, no PrPSc was
detected in tissues from any of the clinically-negative survivors at 525 dpi. Sections were coun-
terstained with haematoxylin to detect cell nuclei (blue). 0.1%-PBS Clin. pos, n = 3 mice; 0.1%-
PBS Clin. neg, n = 5 mice; 0.1%-RANKL Clin. pos, n = 7 mice; 0.1%-RANKL Clin. neg, n = 1
mouse.
(TIF)
S4 Fig. RANKL-treatment does not facilitate prion accumulation in the Peyer’s patches
and mesenteric lymph nodes (MLN) of RANKΔIEC mice orally exposed to prions. RAN-
KΔIEC mice were treated daily for 4 d with RANKL and orally-exposed to a 1% dose of ME7
scrapie prions between the 3rd and 4th treatments. Wild-type (WT) mice orally-exposed to pri-
ons alone were included as a control. At 105 days post-infection, heavy accumulations of PrPSc
(PET immunoblot, black, arrows) in association with FDC (CD21/35+ cells, brown, arrows)
were clearly evident in the Peyer’s patches and MLN of WT mice (left-hand panels). In con-
trast, no PrPSc accumulation was observed in tissues from the RANKL-treated RANKΔIEC
mice orally exposed to prions (right-hand panels). Sections were counterstained with haema-
toxylin to detect cell nuclei (blue). Images are representative of tissues from 4 mice/group.
(TIF)
S5 Fig. Primary antibody controls. Images of Peyer’s patches showing typical examples of the
immunostaining obtained with the primary Ab used in this study (first and third columns)
and their corresponding negative controls (second and fourth columns). Sections were
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counterstained with DAPI (blue) to detect cell nuclei. The antibody concentrations or dilu-
tions used are indicated. All scale bars = 50 μm.
(TIF)
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